CTOs on the Move

ANI Pharmaceuticals

www.anipharmaceuticals.com

 
ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Funding

ANI Pharmaceuticals raised $125M on 12/29/2017
ANI Pharmaceuticals raised $75M on 11/03/2021

Similar Companies

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sunrise Pharmaceutical Inc

Sunrise Pharmaceutical Inc is a Rahway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareMount Medical

We have a number of positions available in our modern medical offices conveniently located at 90 and 110 South Bedford Road in Mount Kisco, as well as openings in our off-site offices in Yorktown, Katonah, Carmel, Fishkill, Poughkeepsie, Somers, Mahopa...

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

MOLLI Surgical

#Healthcare needs to get simpler to get better. To achieve this, we focus on the #patientexperience and develop more effective #medicaldevices. #breastcancer